SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cui, J. Articles by Ginsburg, D. Search for Related Content PubMed PubMed Citation Articles by Cui, J. Articles by Ginsburg, D. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 December 2000, Vol. 96, No. 13, pp. 4222-4226 HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Spontaneous thrombosis in mice carrying the factor V Leiden mutation Jisong Cui, Daniel T. Eitzman, Randal J. Westrick, Patricia D. Christie, Zuojun J. Xu, Angela Y. Yang, Anjali A. Purkayastha, Tony L. Yang, Alan L. Metz, Kim P. Gallagher, Julia A. Tyson, Robert D. Rosenberg, and David Ginsburg From the Divisions of Medical Genetics and Cardiology, Department of Internal Medicine, Department of Human Genetics, and the Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor MI; Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co, Ann Arbor, MI; and the Department of Biology, Massachusetts Institute of Technology, Cambridge, MA.     Abstract Top Abstract Introduction Materials and methods Results and discussion References A polymorphism in coagulation factor V, factor V Leiden (FVL), is the major known genetic risk factor for thrombosis in humans. Approximately 10% of mutation carriers experience clinically significant thrombosis in their lifetime. In a small subset of patients, thrombosis is associated with coinheritance of other prothrombotic gene mutations. However, the potential contribution of additional genetic risk factors in the majority of patients remains unknown. To gain insight into the molecular basis for the variable expressivity of FVL, mice were generated carrying the homologous mutation (R504Q [single-letter amino acid codes]) inserted into the endogenous murine Fv gene. Adult heterozygous (FvQ/+) and homozygous (FvQ/Q) mice are viable and fertile and exhibit normal survival. Compared with wild-type mice, adult FvQ/Q mice demonstrate a marked increase in spontaneous tissue fibrin deposition. No differences in fetal development or survival are observed among FvQ/Q, FvQ/+ or control littermates on the C57BL/6J genetic background. In contrast, on a mixed 129Sv-C57BL/6J genetic background, FvQ/Q mice develop disseminated intravascular thrombosis in the perinatal period, resulting in significant mortality shortly after birth. These results may explain the high degree of conservation of the R504/R506 activated protein C cleavage site within FV among mammalian species and suggest an important contribution of other genetic factors to the thrombosis associated with FVL in humans. (Blood. 2000;96:4222-4226) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results and discussion References Factor V (FV) together with the serine protease factor Xa forms the prothrombinase complex that converts prothrombin to active thrombin. Deficiency of FV results in a major bleeding disorder in humans,1 and genetically engineered mice that are completely deficient in FV exhibit partial lethality at mid-embryogenesis, with the remaining animals dying of hemorrhage at birth.2 FV plays a central regulatory role in hemostasis. It is synthesized as an inactive precursor and is activated to FVa by thrombin cleavage.3 FVa is subsequently inactivated by the natural anticoagulant activated protein C (APC), which cleaves FVa at amino acids R506 (single-letter amino acid code), R306, and R679 in the heavy chain.4,5 Kinetic studies have demonstrated that cleavage occurs first at R506, an event required for efficient cleavage at the other 2 sites. The substitution of Q for R506 in FV, also known as FV Leiden (FVL), has a prevalence of 2% to 7% in most European populations6,7 and is identified in 20% to 50% of patients with venous thrombo-embolic disease.8-10 The lifetime incidence of thrombosis is approximately 10% in heterozygotes and 80% in homozygotes.11-13 Despite the negative evolutionary selection that might be expected from this potentially fatal disorder, the variant allele is present at a remarkably high frequency in European populations ( 0.03) and appears to have arisen from a single founder, who is estimated to have lived 21 000 to 34 000 years ago.14 To explore the molecular basis for the incomplete penetrance and variable expressivity of the FVL mutation, we generated mice carrying the homologous mutation (R504Q) by a gene-targeting "knock-in" approach. Homozygous FVL (FvQ/Q) mice exhibit biochemical evidence for spontaneous fibrin deposition in multiple tissues. In addition, a marked variability in the thrombophilic phenotype is observed dependent on strain background, identifying one or more modifier genes in the 129Sv strain that interact with FVL to produce fatal thrombosis in the perinatal period.     Materials and methods Top Abstract Introduction Materials and methods Results and discussion References Introduction of the R504Q mutation into murine embryonic stem cells by homologous recombination A portion of the murine Fv gene was cloned from a 129Sv library as previously described.2 The homologous arms of the targeting vector were assembled from a 15-kilobase (kb) lambda phage clone containing exons 7 to 11 of the murine Fv gene (Figure 1A). The R504Q mutation was introduced by site-directed mutagenesis (Muta-Gene mutagenesis kit, Bio-Rad, Hercules, CA), according to the manufacturer's instructions, into an approximately 5-kb SalI(vector-derived)/BamHI fragment containing exons 8 through 11 subcloned into pBluescript. The mutagenesis oligonucleotide (antisense) was 5'-CCTGTACACCCTG(CT)CTGGTCCAGG-3', in which the underlined nucleotides represent the mutation, with the native sequence in parentheses. An approximately 1-kb SphI/HpaI fragment containing exons 9 and 10 and the introduced mutation was then subcloned back into an 11.8-kb Fv gene fragment (from the NcoI site in intron 6 to a vector-derived [plasmid vector pSL301] SalI site in intron 11) cloned in Bluescript (Figure 1A). The presence of the mutation and the integrity of the entire SphI/HpaI mutagenesis-derived fragment were confirmed by DNA sequence analysis. A 3.7-kb SalI/XhoI TK/neo-cassette flanked by loxP sites from the vector pFlox (gift of J. Marth, Univ of California, San Diego, La Jolla, CA) was subcloned into the SmaI site in intron 10 of the above-mentioned mutagenized Fv genomic segment. The resulting construct contains Fv exons 7 through 11 with the R504Q mutation inserted into exon 10, the TK/neo selectable marker in intron 10, with a 9.4-kb homologous 5' arm and a 2.4-kb 3' arm (Figure 1A). This targeting vector was linearized with SfiI and introduced into 129Sv-derived D3 embryonic stem (ES) cells (kindly provided by T. Doetschman, University of Cincinnati) by electroporation, and stable transfectants were selected as previously described.2 Individual ES clones were screened for homologous recombination by Southern blot analysis with an exon 13 probe (Figure 1B). The presence of a single-copy TK/neo gene insertion at the expected site was also confirmed by Southern blotting with a neo probe (data not shown). We obtained 5 correctly targeted ES cell clones carrying the TK/neo-cassette from 50 neo (G418) resistant colonies, yielding a 10% targeting efficiency. However, only 3 of the 5 targeted clones contained the R504Q mutation as detected by Mn1I digestion of the polymerase chain reaction (PCR) product amplified from exon 10 of ES cell DNA (data not shown). View larger version (40K): [in this window] [in a new window]   Figure 1. Generation of the FvR504Q "knock-in" allele by gene targeting. (A) Structure of the FV gene (from exons 7 through 13), targeting vector carrying the R504Q mutation in exon 10 and selectable TK/neo cassette flanked by loxP sites, and the expected results of successful homologous recombination and Cre excision of the TK/neo cassette. (B) Southern blot analysisusing the exon 13 probe indicated in panel Aof DNA prepared from targeted ES cells following digestion with EcoRV. Lanes 1 and 2 show only the germline band at 23 kb. Lane 3 shows a successfully targeted ES clone with the predicted 12.5-kb band from the recombined allele and the 23-kb band from the remaining allele. (C) Southern blot analysis using same probe as in panel 1B to detect ES clones that had undergone Cre-mediated excision as shown in lanes 3 and 5 by the absence of the 12.5-kb EcoRV fragment. (D) PCR analysis of wild-type and mutant Fv alleles using primers that cross the insertion site in intron 10. Amplification of DNA from the wild-type allele yields a 124-bp fragment, and DNA from the mutant allele produces a 263-bp fragment. Effect of inserted loxP sequence on intron 10 splicing efficiency The targeting vector shown in Figure 1A was transformed into Escherichia coli strain K1062(Cre), resulting in excision of the TK/neo cassette and an intron 10 structure identical to that predicted for the targeted ES clones following Cre-mediated excision (see below). We subcloned 5-kb BamHI/NotI genomic fragments from the Cre-excised vector and the original genomic clone (containing exons 10 and 11, and intron 10 with or without the loxP element), into the vector pSPL3 and transiently transfected into COS-1 cells by Lipofectamine (Gibco BRL), according to the manufacturer's instructions. PCR primers specific to exons 10 and 11 amplified the same single band corresponding to the expected correctly spliced product, with similar quantities observed in either the presence or the absence of the loxP fragment (data not shown). These data indicate that the presence of the 139-base pair (bp) insertion in intron 10 (containing the single loxP site and flanking vector-derived linker sequences) does not significantly alter Fv intron 10 splicing. Production of FvQ/Q mice To remove the TK/neo-cassette from intron 10 in the targeted ES cells, 10µg of supercoiled pMC-Cre plasmid DNA (gift of J. Marth) was transiently transfected into the targeted ES clones that contained the R504Q mutation by electroporation under the same conditions as for the stable transfectants. After electroporation, the mixture was immediately diluted with medium and then plated out at 100, 103, and 104 colonies per 100-mm plate, assuming a 50% killing rate. The cells were grown for 9 to 10 days in the absence of antibiotic selection, and individual colonies were isolated for screening by Southern blot analysis by means of the same probe as above. Of the unselected clones, 15% were found to have undergone the TK/neo excision event. Successfully targeted ES clones carrying the FvR504Q mutation and the excised TK/neo cassette were injected into C57BL/6J mouse blastocysts as previously described.2 The presence of the mutation in representative mice derived from each of the original 3 independent ES cell colonies was verified by DNA sequencing of mouse genomic DNA amplified by PCR with primers 5'-TTGCCTCTGGGCTGATAGGG-3' (in exon 10) and 5'- CCTAATCTGTGCCAGCG-3' (in intron 10). Since the R504Q mutation is separated from the intron 10 loxP insertion by only 400 bp, the presence of the latter was subsequently used as a size marker for rapid PCR genotyping. The intron 10 primers 5'-CCTCTGGACTCTGACTGCAG- 3' and 5'-TATTCTGGACTACAAGAGTGAG-3' flank the 139-bp insertion containing the loxP site, amplifying fragments of 263 bp and 124 bp from the R504Q and wild-type Fv alleles, respectively (Figure 1D). Chimeric founder males were bred to C57BL/6J females (The Jackson Laboratory, Bar Harbor, ME) to generate F1 heterozygous offspring. Homozygous R504Q mice were obtained from F1 intercrosses. For most experiments, R504Q mice were backcrossed to C57BL/6J mice for 4 generations (N4), and N4 R504Q heterozygous mice were intercrossed to produce homozygous offspring. For additional analysis of mutant mice on a mixed 129Sv-C57BL/6J genetic background, C57BL/6J N4 R504Q homozygous mice were crossed back to 129Sv/J or 129SvIm/J (The Jackson Laboratory), and the heterozygous offspring were then intercrossed. Analysis of thrombotic phenotype FV procoagulant activity and APC resistance assays were determined as previously described15 with the use of FvQ/Q, FvQ/+ and Fv+/+ littermates (on a mixed 129Sv-C57BL/6J genetic background).2 Quantitation of tissue fibrin from multiple homogenized tissues was performed in 8-week-old mice as previously described.16 These animals (Figure 3) were littermates from an intercross of FvQ/+ (N4 backcrossed to C57BL/6J). Fetuses and neonates were photographed at autopsy, fixed in 1% glutaraldehyde in 0.1 mol/L phosphate buffer for 1 hour or 10% neutral buffered formalin overnight at room temperature. Fetuses and neonates were decalcified for 15 hours in formic acid, and then heads were removed and bodies were split sagittally just off midline. Heads were embedded in paraffin to provide coronal sections, and bodies were embedded in paraffin for sagittal sectioning. All fetuses and neonates were step-sectioned (3 to 6 µm thick) for light microscopic evaluation taken every 250 µm. Embryo/fetuses and adult tissues were stained with hematoxylin and eosin.     Results and discussion Top Abstract Introduction Materials and methods Results and discussion References Generation of mice carrying the Fv R504Q mutation We introduced the R504Q mutation into the endogenous murine Fv gene by homologous recombination. This mutation in murine FV has previously been shown to result in partial APC resistance in vitro, comparable to the effect of the homologous R506Q mutation in human FV.15,17 A targeting vector carrying the R504Q mutation in exon 10 and a TK/neo-expression cassette flanked by loxP sites in intron 10 (Figure 1A) was transfected into 129Sv ES cells. Successfully targeted clones were identified by Southern blotting (Figure 1B). We obtained 5 correctly targeted ES cell clones, 3 of which contained R504Q, indicating that homologous recombination in these clones had occurred upstream of this mutation in the 5' arm of the targeting vector (data not shown). The occurrence of 2 homologous recombination events in the 400-bp region between the mutation and the TK/neo-cassette and only 3 events in the 9400-bp region upstream of the mutation suggests a possible recombination "hot spot" at the junction of the genomic and synthetic sequences. Transfection of successfully targeted ES clones with a Cre expression plasmid (pMC-Cre) catalyzed recombination between the loxP sites, resulting in excision of the TK/neo-cassette, leaving behind only a 139-bp fragment within intron 10 containing a single loxP element (Fig. 1A,C,D). Reverse transcription PCR (RT-PCR) analysis of COS-1 cells transfected with modified Fv genomic fragments demonstrated that the efficiency of intron 10 splicing was not altered by the presence of this small loxP segment insertion (see "Materials and methods"). FV activity and APC resistance in FVL mice Chimeric male mice generated from ES cells carrying the R504Q mutation after excision of the TK/neo-cassette were bred to C57BL/6J females, and F1 heterozygous (FvQ/+) offspring were intercrossed to generate homozygous R504Q (FvQ/Q) mice. No obvious differences were observed among litters obtained from chimeric founders corresponding to each of the original 3 independently targeted ES clones. Progeny derived from a single founder were selected to establish the colony FV clotting activities measured in adult FvQ/Q and FvQ/+ mice were indistinguishable from those of wild-type Fv+/+ mice. Taken together with our previous data that the R504Q mutation does not affect the procoagulant activity of FV in vitro,15 these results indicate that gene expression from the targeted Fv allele is equivalent to wild-type and that the biosynthesis, processing, and clearance of murine FV are not altered by the FVL mutation. However, plasma APC resistance was conferred by the R504Q mutation in a dose-dependent manner, similar to that observed in humans with FV Leiden (APC resistance ratio, 2.1 ± 0.3 for Fv+/+, 1.5 ± 0.1 for FvQ/+, and 1.3 ± 0.1 for FvQ/Q mice). Spontaneous thrombosis and increased tissue fibrin content in FvQ/Q mice FvQ/+ mice were grossly indistinguishable from their normal littermates except for a rare, sporadic thrombo-embolic event as illustrated in Figure 2. This pattern is comparable to the mild phenotype observed in human FVL patients in whom similar sporadic events occur with a lifetime penetrance of  10%.2 View larger version (110K): [in this window] [in a new window]   Figure 2. Spontaneous vascular thrombosis. Spontaneous vascular thrombosis in 6-week-old FvQ/+ mouse resulted in necrotic toe (N4 C57BL/6J background). Because of the potentially confounding effect of the mixed 129Sv and C57BL/6J background, FvQ/+ mice were serially backcrossed to the C57BL/6J strain for 4 generations (N4), and intercrosses of these N4 animals were used to generate the FVQ/Q and FvQ/+ mice employed in subsequent experiments. Adult FvQ/Q mice on both the mixed 129Sv-C57BL/6J and the C57BL/6J N4 backgrounds appeared healthy and routinely survived to more than 1 year of age, with females exhibiting normal fertility and uncomplicated pregnancies. Routine histopathologic analysis of 6- to 8-week-old FvQ/Q mice revealed occasional focal hepatic fibrosis but was otherwise unremarkable. Analysis of tissue fibrin content in 8-week-old adult FvQ/Q mice16 showed biochemical evidence for chronic, low-grade thrombin generation leading to enhanced fibrin deposition in multiple tissues (Figure 3). Increased tissue fibrin deposition has also been demonstrated by the use of these methods in mice carrying a mutant thrombomodulin gene with reduced capacity to generate APC.16 These results suggest that similar subclinical chronic fibrin deposition may be occurring in human FVL patients, with the potential for long-term organ damage. This latter hypothesis is supported by the observation of increased circulating thrombin-antithrombin complexes in some human studies18,19 although it is not confirmed in others.20 View larger version (17K): [in this window] [in a new window]   Figure 3. Tissue fibrin deposition in various organs in FvQ/Q and Fv+/+ mice. Tissue fibrin deposition in various organs is elevated in FvQ/Q mouse (n = 5) compared with Fv+/+ mice (n = 5). Open bars represent FvQ/Q mice, and hatched bars represent Fv+/+ mice. Lethal perinatal thrombosis in FvQ/Q mice on 129Sv genetic background Although intercrosses between F1 FvQ/+ mice on the original mixed 129Sv-C57BL/6J background produced viable FvQ/Q offspring that survived to adulthood, the expected number of FvQ/Q pups observed at 3 weeks of age was significantly decreased from what was expected (Table 1).                                View this table: [in this window] [in a new window]   Table 1. Genotype distribution of progeny at 3 weeks of age or at 18.5 days postconception When offspring from F1 intercrosses were retrieved and genotyped at 18.5 days postconception (DPC) (approximately 1 to 2 days before birth), the expected number of FvQ/Q fetuses was observed (Table 1), indicating that the deficiency of FvQ/Q pups at 3 weeks is due not to embryonic loss, but rather to increased mortality in the perinatal or newborn period. Intercrosses performed between surviving adult F2 FvQ/Q mice generated litters of entirely FvQ/Q offspring, with a subset appearing pale and lethargic at birth. Histological analysis demonstrated widespread thrombosis affecting multiple organs, including brain, liver, heart, pancreas, and spleen, in all FvQ/Q newborns, though of varying severity (Figure 4). View larger version (158K): [in this window] [in a new window]   Figure 4. Microscopic findings in neonatal homozygous FvQ/Q mice. (A) Atrial thrombosis involving predominantly the left atrium with small right atrial thrombus attached to atrial septum (bar = 300µ). (B) Brain microthrombi (arrowheads), thalamic region (bar = 150µ). (C) Hepatic thrombus (arrows) with associated area of infarction (asterisk) (bar = 150µ). (D) Large thrombus (arrows) in mesentery adjacent to pancreas (bar = 300µ). All sections are stained with hematoxylin and eosin (H&E) (sections are from mice on a mixed 129Sv-C57BL/6J). Thrombosis was also seen in FvQ/Q fetuses examined at 18.5 DPC although it was much less pronounced. In contrast, histologic evidence for thrombosis was not observed in FvQ/+ or Fv+/+ newborns (data not shown). Thus, homozygosity for FVL is associated with spontaneous thrombosis during late fetal development that is accentuated at the time of birth, leading to perinatal mortality in a subset of mice. These data are in striking contrast to humans, where individuals with FVL exhibit normal survival.21 Although some reports suggest enhanced early pregnancy loss in FVL heterozygous females,22-24 the prevalence of homozygosity for FVL is consistent with Hardy-Weinberg equilibrium,25 arguing against significant selective loss of FVL homozygotes from human populations. Although neonatal thrombosis in human FVL appears to be rare, the pathology observed in newborn FvQ/Q mice closely resembles the lethal neonatal purpura fulminans observed in humans with homozygous protein C deficiency,26 a more severe defect in the same natural anticoagulant pathway. Homozygous protein C deficiency in mice (Pc/) causes a profound consumptive coagulopathy that is uniformly lethal at or before birth, also appearing somewhat more severe than its human counterpart, though this difference may be due to low levels of residual protein C activity in most human patients.27 Histologic findings in Pc/ mice resemble the disseminated thrombosis observed in FvQ/Q mice (Figure 4), though more widespread and with a more pronounced hemorrhagic component. The dramatically more severe consequences of FvQ/Q in mice than in humans may result from differences in hemostatic balance during a critical perinatal period. A recent evolutionary shift in this balance may account for the apparent tolerance of the R506Q mutation in humans, despite the high degree of conservation of the R504/R506 APC cleavage site among other mammalian species. Evidence for one or more genetic modifier genes for FVL among inbred mouse strains In contrast to the selective loss of FvQ/Q pups observed in the mixed 129Sv-C57BL/6J genetic background, an intercross of FvQ/+ mice from an N4 backcross to C57BL/6J produced the expected number of FvQ/Q offspring (Table 1). These results suggest the influence of strain-specific modifying factors accounting for this marked variation in neonatal mortality. To confirm the presence of a genetic modifier and exclude the influence of an unrecognized environmental factor, FvQ/Q N4 C57BL/6J mice were again crossed with Fv wild-type mice of the 129Sv strain, and intercrosses of heterozygous F1 offspring examined. The observed genotypes were again consistent with perinatal loss of approximately 50% of FvQ/Q progeny. It is interesting to note that the 129 background is also associated with increased fetal loss in tissue factor-deficient mice,28 though presumably through a different mechanism that either perturbs yolk sac vascular development or exacerbates the hemorrhagic defect, in contrast to the prothrombotic effect of the 129 modifier on FVL. Analysis of similar mouse models have demonstrated the presence of significant genetic modifiers for other important human diseases, including cystic fibrosis29 and hereditary hemorrhagic telangiectasia.30 Taken together, these data demonstrate that one or more variable genetic loci in the mouse exert a profound modifying influence on the FVL thrombotic phenotype. The incomplete penetrance of thrombosis in humans with FVL also suggests an important role for genetic modifiers. Consistent with this hypothesis, co-inheritance of mutations in other prothrombotic genes, such as protein C,31 protein S,32 antithrombin III,33 and prothrombin,34 has been shown to increase the incidence of vascular thrombosis in FVL humans. However, most of these latter genetic risk factors are uncommon, and co-inheritance with FVL can account for only a small subset of the thrombosis that occurs in carriers of the FVL mutation. Our results demonstrate the presence of genetic variation in the mouse similar to that observed in humans and suggest that characterization of these murine modifier genes could have important implications for understanding the incomplete penetrance of FVL in humans. Yin et al35 recently demonstrated that the murine FVL mutation reported here unmasks a thrombotic phenotype in protein Z-deficient mice, providing the first direct evidence for the in vivo antithrombotic function of protein Z. In addition to protein Z, potential candidates for both the murine and the human genetic modifiers of FVL include nearly all of the known components of hemostasis. Subtle alterations at one of more of these loci could prove difficult to detect in complex human populations but may be more easily approached in the mouse.36     Footnotes Submitted July 11, 2000; accepted August 22, 2000. Supported by National Institutes of Health grants HL-035989 and 036195 (D.E.), P01-41484 (R.D.R. and P.D.C.), and HL-57345 (D.G.). D.G. is a Howard Hughes Medical Institute investigator. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: David Ginsburg, Howard Hughes Medical Institute, University of Michigan Medical Center, 4520 MSRB I, 1150 West Medical Center Dr, Ann Arbor, MI 48109-0650; ginsburg{at}umich.edu.     References Top Abstract Introduction Materials and methods Results and discussion References 1. Tracy PB, Mann KG. Abnormal formation of the prothrombinase complex: factor V deficiency and related disorders. Hum Pathol. 1987;18:162-169[Medline] [Order article via Infotrieve]. 2. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature. 1996;384:66-68[Medline] [Order article via Infotrieve]. 3. Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 1988;71:539-555[Free Full Text]. 4. Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor: purification from human plasma and characterization. J Biol Chem. 1983;258:163-168[Abstract/Free Full Text]. 5. Luckow EA, Lyons DA, Ridgeway TM, Esmon CT, Laue TM. Interaction of clotting factor V heavy chain with prothrombin and prethrombin 1 and role of activated protein C in regulating this interaction: analysis by analytical ultracentrifugation. Biochemistry. 1989;28:2348-2354[Medline] [Order article via Infotrieve]. 6. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343:1536-1538[Medline] [Order article via Infotrieve]. 7. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343:1535-1536[Medline] [Order article via Infotrieve]. 8. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522[Abstract/Free Full Text]. 9. Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 1993;82:1989-1993[Abstract/Free Full Text]. 10. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506[Medline] [Order article via Infotrieve]. 11. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67[Medline] [Order article via Infotrieve]. 12. Greengard JS, Eichinger S, Griffin JH, Bauer KA. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an ArgGln mutation in the gene for factor V. N Engl J Med. 1994;331:1559-1562[Free Full Text]. 13. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508[Abstract/Free Full Text]. 14. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997;89:397-402[Abstract/Free Full Text]. 15. Yang TL, Cui J, Rehumtulla A, et al. The structure and function of murine factor V and its inactivation of protein C. Blood. 1998;91:4593-4599[Abstract/Free Full Text]. 16. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest. 1998;101:1983-1991[Medline] [Order article via Infotrieve]. 17. Heeb MJ, Rehemtulla A, Moussalli M, Kojima Y, Kaufman RJ. Importance of individual activated protein C cleavage site regions in coagulation Factor V for Factor Va inactivation and for Factor Xa activation. Eur J Biochem. 1999;260:64-75[Medline] [Order article via Infotrieve]. 18. Martinelli I, Bottasso B, Duca F, Faioni E, Mannucci PM. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost. 1996;75:703-705[Medline] [Order article via Infotrieve]. 19. Simioni P, Scarano L, Gavasso S, et al. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol. 1996;92:435-441[Medline] [Order article via Infotrieve]. 20. Eichinger S, Weltermann A, Philipp K, et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost. 1999;82:1232-1236[Medline] [Order article via Infotrieve]. 21. Hille ETM, Westendorp RGJ, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood. 1997;89:1963-1967[Abstract/Free Full Text]. 22. Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Int Med. 1998;128:1000-1003. 23. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;1:9-13. 24. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342:374-380[Abstract/Free Full Text]. 25. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA. 1997;277:1305-1307[Abstract]. 26. Marciniak E, Wilson HD, Marlar RA. Neonatal purpura fulminans: a genetic disorder related to the absence of protein C in blood. Blood. 1985;65:15-20[Abstract/Free Full Text]. 27. Jalbert L, Rosen E, Moons L, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest. 1998;102:1481-1488[Medline] [Order article via Infotrieve]. 28. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood. 1996;88:1583-1587[Abstract/Free Full Text]. 29. Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet. 1996;12:280-287[Medline] [Order article via Infotrieve]. 30. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest. 1999;104:1343-1351[Medline] [Order article via Infotrieve]. 31. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84:1031-1035[Abstract/Free Full Text]. 32. Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1995;85:3518-3523[Abstract/Free Full Text]. 33. Van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 1996;75:417-421[Medline] [Order article via Infotrieve]. 34. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999;341:801-806[Abstract/Free Full Text]. 35. Yin Z-F, Huang Z-F, Cui J, et al. Prothrombotic phenotype or protein Z deficiency [abstract]. Blood. 1999;94:367a. 36. Frankel WN. Taking stock of complex trait genetics in mice. Trends Genet. 1995;11:471-477[Medline] [Order article via Infotrieve]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Zhang, Y. Tu, L. Lu, N. Lasky, and G. J. Broze Jr Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency Blood, May 15, 2008; 111(10): 4973 - 4978. [Abstract] [Full Text] [PDF] Y. Cheli, D. Jensen, P. Marchese, D. Habart, T. Wiltshire, M. Cooke, J. A. Fernandez, J. Ware, Z. M. Ruggeri, and T. J. Kunicki The Modifier of hemostasis (Mh) locus on chromosome 4 controls in vivo hemostasis of Gp6-/- mice Blood, February 1, 2008; 111(3): 1266 - 1273. [Abstract] [Full Text] [PDF] R. J. Westrick, M. E. Winn, and D. T. Eitzman Murine Models of Vascular Thrombosis Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2079 - 2093. [Abstract] [Full Text] [PDF] R. Sood, M. Zogg, R. J. Westrick, Y.-h. Guo, E. J. Kerschen, G. Girardi, J. E. Salmon, S. R. Coughlin, and H. Weiler Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers J. Exp. Med., May 14, 2007; 204(5): 1049 - 1056. [Abstract] [Full Text] [PDF] X. SHEN and K. E. BORNFELDT Mouse Models for Studies of Cardiovascular Complications of Type 1 Diabetes Ann. N.Y. Acad. Sci., April 1, 2007; 1103(1): 202 - 217. [Abstract] [Full Text] [PDF] Y. Shen, P. F. Bodary, F. B. Vargas, J. W. Homeister, D. Gordon, K. A. Ostenso, J. A. Shayman, and D. T. Eitzman {alpha}-Galactosidase A Deficiency Leads to Increased Tissue Fibrin Deposition and Thrombosis in Mice Homozygous for the Factor V Leiden Mutation Stroke, April 1, 2006; 37(4): 1106 - 1108. [Abstract] [Full Text] [PDF] N. Mackman Tissue-Specific Hemostasis in Mice Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2273 - 2281. [Abstract] [Full Text] [PDF] S. R. Lentz Another Lesson From the Factor V Leiden Mouse: Thrombin Generation Drives Arterial Disease Circulation, April 12, 2005; 111(14): 1733 - 1734. [Full Text] [PDF] D. T. Eitzman, R. J. Westrick, Y. Shen, P. F. Bodary, S. Gu, S. L. Manning, S. L. Dobies, and D. Ginsburg Homozygosity for Factor V Leiden Leads to Enhanced Thrombosis and Atherosclerosis in Mice Circulation, April 12, 2005; 111(14): 1822 - 1825. [Abstract] [Full Text] [PDF] A. C. Parker, L. V. Mundada, A. H. Schmaier, and W. P. Fay Factor VLeiden Inhibits Fibrinolysis In Vivo Circulation, December 7, 2004; 110(23): 3594 - 3598.